Bright Peak Therapeutics, a developer of cytokine immunotherapies to treat cancer and autoimmune disease, has raised $107 million in Series B financing. RA Capital led the round with participation from other investors that included Versant Ventures, Fidelity Management & Research Company, Invus, Qatar Investment Authority, BlackRock and Alexandria Venture Investments.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: